Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Harbeck, M. Beckmann, A. Rody, A. Schneeweiss, V. Müller, T. Fehm, N. Marschner, O. Gluz, I. Schrader, G. Heinrich, M. Untch, C. Jackisch (2013)HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Breast Care, 8
E. Peles, Y. Yarden (1993)Neu and its ligands: From an oncogene to neural factors
Wei Tang, Yi Lu, Q. Tian, Yan Zhang, F. Guo, Guang-Yi Liu, Nabeel Syed, Y. Lai, E. Lin, L. Kong, Jeffrey Su, F. Yin, A. Ding, A. Zanin-Zhorov, Michael Dustin, J. Tao, J. Craft, Z. Yin, Jian Feng, S. Abramson, Xiu-ping Yu, Chuan-ju Liu (2011)The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice
A. Nykjaer, T. Willnow (2012)Sortilin: a receptor to regulate neuronal viability and function
Trends in Neurosciences, 35
T. Abrhale, A. Brodie, G. Sabnis, L. Macedo, Changsheng Tian, B. Yue, G. Serrero (2011)GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells
BMC Cancer, 11
G. Arpino, L. Wiechmann, C. Osborne, R. Schiff (2008)Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Endocrine reviews, 29 2
R. Nahta, L. Yuan, Bing Zhang, R. Kobayashi, F. Esteva (2005)Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Cancer research, 65 23
M. Tan, Ping Li, K. Klos, Jing Lu, K. Lan, Yoichi Nagata, D. Fang, Tong Jing, Dihua Yu (2005)ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
Cancer research, 65 5
Wisit Tangkeangsirisin, J. Hayashi, G. Serrero (2004)PC Cell-Derived Growth Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of Human Breast Cancer Cells
Cancer Research, 64
P. Janes, R. Daly, A. deFazio, R. Sutherland (1994)Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.
Oncogene, 9 12
G. Lewis, I. Figari, B. Fendly, Wai Wong, P. Carter, C. Gorman, H. Shepard (1993)Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Cancer Immunology, Immunotherapy, 37
P. Carter, L. Presta, C. Gorman, J. Ridgway, D. Henner, Wai Wong, A. Rowland, C. Kotts, M. Carver, H. Shepard (1992)Humanization of an anti-p185HER2 antibody for human cancer therapy.
Proceedings of the National Academy of Sciences of the United States of America, 89
N. Hynes, H. Lane (2004)Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase
Journal of Mammary Gland Biology and Neoplasia, 6
K. Leitzel, Yoshio Teramoto, Kristine Konrad, V. Chinchilli, G. Volas, H. Grossberg, H. Harvey, L. Demers, A. Lipton (1995)Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 5
G. Serrero, O. Ioffe (2003)Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium.
Human pathology, 34 11
W. Kim, G. Serrero (2006)PC Cell–Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells
Clinical Cancer Research, 12
T. Garrett, N. Mckern, M. Lou, T. Elleman, T. Adams, G. Lovrecz, M. Kofler, R. Jorissen, E. Nice, A. Burgess, C. Ward (2003)The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
Molecular cell, 11 2
L. Muynck, Sarah Herdewyn, S. Beel, W. Scheveneels, L. Bosch, W. Robberecht, P. Damme (2013)The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding
Neurobiology of Aging, 34
Wisit Tangkeangsirisin, G. Serrero (2004)PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells.
Carcinogenesis, 25 9
K. Carraway, L. Cantley (1994)A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling
G. Serrero (2003)Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis.
Biochemical and biophysical research communications, 308 3
G. Fiszman, M. Jasnis (2011)Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
International Journal of Breast Cancer, 2011
M. Shupnik (2004)Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation
M. Sliwkowski, J. Lofgren, G. Lewis, T. Hotaling, B. Fendly, J. Fox (1999)Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Seminars in oncology, 26 4 Suppl 12
C. Grandori, S. Cowley, L. James, R. Eisenman (2000)The Myc/Max/Mad network and the transcriptional control of cell behavior.
Annual review of cell and developmental biology, 16
R. Vadlamudi, A. Sahin, L. Adam, Rui‐an Wang, Rakesh Kumar (2003)Heregulin and HER2 signaling selectively activates c‐Src phosphorylation at tyrosine 215
FEBS Letters, 543
I. Alroy, Y. Yarden (1997)The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions
FEBS Letters, 410
D. Yu (2001)Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.
Seminars in oncology, 28 5 Suppl 16
C. Dang, L. Resar, E. Emison, Sunkyu Kim, Qing Li, J. Prescott, Diane Wonsey, K. Zeller (1999)Function of the c-Myc oncogenic transcription factor.
Experimental cell research, 253 1
T. Petkau, B. Leavitt (2014)Progranulin in neurodegenerative disease
Trends in Neurosciences, 37
G. Serrero, D. Hawkins, B. Yue, O. Ioffe, P. Bejarano, J. Phillips, J. Head, R. Elliott, K. Tkaczuk, A. Godwin, J. Weaver, W. Kim (2012)Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma
Breast Cancer Research : BCR, 14
C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, M. Press (2023)Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology, 41
R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. Ratzkin, M. Sela, Y. Yarden (1996)Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
The EMBO Journal, 15
D. Salomon, R. Brandt, F. Ciardiello, N. Normanno (1995)Epidermal growth factor-related peptides and their receptors in human malignancies.
Critical reviews in oncology/hematology, 19 3
Xiaoyan Wang, M. Cunningham, Xiao-li Zhang, Sara Tokarz, Bryan Laraway, M. Troxell, R. Sears (2011)Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.
Cancer research, 71 3
Zhiheng He, A. Bateman (2003)Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis
Journal of Molecular Medicine, 81
E. Tzahar, H. Waterman, Xiomei Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. Ratzkin, Y. Yarden (1996)A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
Molecular and Cellular Biology, 16
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science, 235 4785
H. Burris (2000)Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Seminars in oncology, 27 2 Suppl 3
Siyuan Zhang, Wen-Chien Huang, Ping Li, Hua Guo, Say-Bee Poh, Samuel Brady, Y. Xiong, L. Tseng, Shau-Hsuan Li, Zhaoxi Ding, A. Sahin, F. Esteva, G. Hortobagyi, Dihua Yu (2011)Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Nature Medicine, 17
J. Baselga, S. Swain (2009)Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Nature Reviews Cancer, 9
N. Hynes, D. Stern (1994)The biology of erbB-2/neu/HER-2 and its role in cancer.
Biochimica et biophysica acta, 1198 2-3
D. Tolkatchev, S. Malik, Anna Vinogradova, Ping Wang, Zhigang Chen, P. Xu, H. Bennett, A. Bateman, F. Ni (2008)Structure dissection of human progranulin identifies well‐folded granulin/epithelin modules with unique functional activities
Protein Science, 17
K. Tkaczuk, B. Yue, M. Zhan, N. Tait, Lavanya Yarlagadda, H. Dai, G. Serrero (2011)Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects
Breast Cancer : Basic and Clinical Research, 5
M. Scaltriti, P. Eichhorn, J. Cortés, L. Prudkin, C. Aura, J. Jiménez, S. Chandarlapaty, V. Serra, A. Prat, Y. Ibrahim, M. Guzman, M. Gili, Olga Rodríguez, S. Rodríguez, J. Pérez, S. Green, S. Mai, N. Rosen, C. Hudis, J. Baselga (2011)Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Proceedings of the National Academy of Sciences, 108
X. Chen, Jianjun Chang, Qiudong Deng, Jie Xu, Thi Nguyen, L. Martens, B. Cenik, Georgia Taylor, Kathryn Hudson, Jaegwon Chung, Kimberley Yu, Phillip Yu, J. Herz, Robert Farese, T. Kukar, M. Tansey (2013)Progranulin Does Not Bind Tumor Necrosis Factor (TNF) Receptors and Is Not a Direct Regulator of TNF-Dependent Signaling or Bioactivity in Immune or Neuronal Cells
The Journal of Neuroscience, 33
Gresin Pizarro, Xun Zhou, A. Koch, Mahmood Gharib, Sejal Raval, K. Bible, M. Jones (2007)Prosurvival function of the granulin‐epithelin precursor is important in tumor progression and chemoresponse
International Journal of Cancer, 120
Zhiheng He, C. Ong, J. Halper, A. Bateman (2003)Progranulin is a mediator of the wound response
Nature Medicine, 9
J. Sarup, R. Johnson, King Kl, Fendly Bm, Lipari Mt, Napier Ma, A. Ullrich, H. Shepard (1991)Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Growth regulation, 1 2
J. Halper (2009)Growth Factors as Active Participants in Carcinogenesis: A Perspective
Veterinary Pathology, 47
G. Evan, T. Littlewood (1998)A matter of life and cell death.
Science, 281 5381
R. Lu, G. Serrero (2001)Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor).
Proceedings of the National Academy of Sciences of the United States of America, 98 1
Jinhua Xu, Yinghua Chen, O. Olopade (2010)MYC and Breast Cancer.
Genes & cancer, 1 6
R. Nahta, L. Yuan, B. Zhang, R. Kobayashi, F. Esteva (2008)Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128))
Cancer Research, 68
Wisit Tangkeangsirisin, G. Serrero (2014)GP88 (Progranulin) Confers Fulvestrant (Faslodex, ICI 182,780) Resistance to Human Breast Cancer Cells
Her2 is a receptor tyrosine kinase overexpressed in 25% of breast tumors. We have shown that the 88 kDa autocrine growth and survival factor GP88 (progranulin) stimulated Her2 phosphorylation and proliferation and conferred Herceptin resistance in Her2-overexpressing cells. Herein, we report that GP88 stimulates c-myc phosphorylation and upregulates c-myc levels in Her2-overexpressing cells. c-myc phosphorylation and upregulation by GP88 were not observed in non-Her2-overexpressing breast cancer cells. c-myc activation was inhibited upon treatment with ERK, PI3 kinase, and c-src pathway inhibitors, U0126, LY294002, and PP2. GP88 also stimulated c-src phosphorylation, a known upstream regulator of c-myc. Thus, we describe here a signaling pathway for GP88 in Her2-overexpressing cells, with GP88 stimulating Src phosphorylation, followed by phosphorylation and upregulation of c-myc. These data would suggest that targeting GP88 could provide a novel treatment approach in breast cancer.
Breast Cancer: Basic and Clinical Research – SAGE
Published: May 5, 2016
Keywords: GP88; progranulin; c-myc; breast cancer; Her2
Access the full text.
Sign up today, get DeepDyve free for 14 days.